Latham & Watkins Advises Syneos Health in Secondary Offering of Common Stock

Capital markets team represented the biopharmaceutical solutions organization in the offering.

March 03, 2021

Latham & Watkins advised Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), in its underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 7 million shares of the Company’s common stock at a price to the public of US$74.95 per share. The Selling Stockholders have also granted the underwriter a 30-day option to purchase up to 1,050,000 additional shares of common stock. The Offering closed on March 3, 2021.

Latham & Watkins LLP represented Syneos Health in the offering with a capital markets team led by New York partners Keith Halverstam and Adam Gelardi, with New York associates Will Clark and MacLane Taggart. Advice was also provided on tax matters by New York partners Elena Romanova and Jocelyn Noll, with New York associate Sam Yang.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.